Most popular peptide claims start from something real, usually an animal study, a short human hormone study, or an approved drug's label, and then stretch it well past what the data show. Of the ten claims below, only a few rest on solid human evidence, and those mostly involve FDA-approved drugs in specific patient groups. The research-only favorites, BPC-157 and TB-500 above all, are still overwhelmingly animal and cell data.
How we grade the evidence
| Tier | What it means |
|---|---|
| A | FDA-approved use, or consistent randomized human trials on outcomes that matter |
| B | Some randomized human trials, but small, short or in different populations |
| C | Human physiology or uncontrolled human reports only |
| D | Animal or cell studies only |
1. "BPC-157 heals tendons in humans"
Grade: D, with one weak C data point. A 2025 systematic review in HSS Journal looked at BPC-157 in orthopaedic sports medicine and included 36 studies. Thirty-five were preclinical. The single clinical study was a retrospective report of 12 patients with unspecified chronic knee pain who got one injection into the knee; 7 reported improvement lasting more than six months. There was no control group, and the outcome was self-reported. The authors concluded that the lack of clinical outcome and safety data "prevents us from proposing evidence-based practice use guidelines." Our BPC-157 preclinical research review covers the animal work in detail.
2. "BPC-157 is legal now after the FDA vote"
Grade: false as stated. The July 2026 advisory committee recommendation was non-binding. It didn't approve BPC-157 as a drug, and it didn't place it on the 503A bulks list. That takes FDA action. BPC-157 remains not FDA-approved, and research-grade product is not sold for human use. Our PCAC vote breakdown explains each step.
3. "Growth hormone secretagogues are basically HGH"
Grade: misleading. Secretagogues like ipamorelin and MK-677, and GHRH analogues like CJC-1295 and sermorelin, work by prompting your own pituitary to release growth hormone. That isn't the same as injecting growth hormone, because the response depends on your pituitary and on normal feedback. We couldn't find randomized trials showing that research secretagogues build muscle or strength in healthy, trained men. The one thing they do share with HGH: WADA bans all of them. See our CJC-1295 vs tesamorelin comparison.
4. "TB-500 is just thymosin beta-4, so the human research applies"
Grade: D for TB-500 itself. TB-500 is marketed as a fragment or derivative of thymosin beta-4. WADA lists "thymosin-β4 and its derivatives, e.g. TB-500" together for anti-doping purposes, but sharing a parent molecule doesn't transfer evidence. We found no controlled human trials of TB-500 for muscle or tendon injury. See BPC-157 vs TB-500.
5. "Kisspeptin boosts testosterone"
Grade: C. This one has real human data. In University of Edinburgh studies, intravenous kisspeptin-10 raised LH in healthy men, and in a longer high-dose infusion in four men, testosterone rose from 16.6 to 24.0 nmol/L. But these were short, supervised infusions measuring hormones, not muscle, strength or fertility. Kisspeptin isn't approved for any use.
6. "NAD+ boosters give you more energy"
Grade: B for raising blood NAD+, unsupported for benefits. A 2025 meta-analysis of randomized NMN trials found that most raised blood NAD+, but found no significant improvement in glucose, insulin, HbA1c, BMI or blood pressure. We found no randomized outcome trials of injected or IV NAD+ in healthy adults. Full breakdown in NAD+ injections vs NMN and NR.
7. "GHK-Cu reverses skin aging"
Grade: C at best for topical use. A 2024 review of topical GHK as an anti-wrinkle peptide described "a surprising absence of clinical studies." The human data are one small 1998 pilot study and two 2002 conference abstracts. The strongest evidence is from cell work. Copper peptide skincare is legal and widely sold; the claim outruns the trials.
8. "GLP-1s burn fat, not muscle"
Grade: false as stated. In the STEP 1 trial's body-composition substudy, about 38 to 39% of weight lost on semaglutide was classified as lean mass on DXA. Some of that isn't muscle, and strength data are mixed, but "fat only" isn't what the trials found. Resistance training and adequate protein are the countermeasures.
9. "Tesamorelin melts belly fat for anyone"
Grade: A in its approved population, unknown outside it. Tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, and its trials measured visceral fat by CT. Whether that effect carries over to healthy lifters with ordinary belly fat hasn't been shown in comparable trials.
10. "A COA means the peptide is safe"
Grade: false as stated. A certificate of analysis tells you what a lab found in a tested sample: identity and purity, and sometimes more. It doesn't establish sterility unless that was tested, it doesn't guarantee your vial matches the tested lot, and it says nothing about whether the compound is safe or effective in humans. Our COA guide shows what to look for.
The scorecard
| # | Claim | Verdict |
|---|---|---|
| 1 | BPC-157 heals tendons in humans | Mostly animal data |
| 2 | BPC-157 is legal after the vote | False |
| 3 | Secretagogues are basically HGH | Misleading |
| 4 | TB-500 inherits thymosin β4 research | No direct human evidence |
| 5 | Kisspeptin boosts testosterone | Short-term human hormone data |
| 6 | NAD+ boosters give energy | Blood levels yes, benefits unshown |
| 7 | GHK-Cu reverses skin aging | Thin human data |
| 8 | GLP-1s burn only fat | False |
| 9 | Tesamorelin for anyone's belly fat | Proven only in its approved group |
| 10 | A COA means it's safe | False |
How to check the next claim yourself
- Ask: humans or animals? Most peptide headlines trace back to rodents.
- Ask: what was measured? A hormone level isn't a strength gain, and a blood level isn't a health outcome.
- Ask: who was studied? Results in patients with a specific disease don't automatically apply to healthy lifters.
- Ask: was there a control group? Without one, you can't separate the drug from time, rest and expectation.
- Ask: is it approved, and for what? An approval comes with a label you can read.
Research vendors we link to
For readers doing laboratory research, these are vendors we link to. Read the batch COA before ordering, and remember claim 10.
Dosing for prescription peptides is set by the prescribing clinician. Research-use-only peptides are not sold for human use and have no approved human dose. See our medical disclaimer. Tested athletes should read our WADA list breakdown first.
Sources
- Vasireddi N et al., Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review, HSS J 2025;21(4):485–495 (PMC12313605).
- George JT et al., J Clin Endocrinol Metab 2011;96(8):E1228–E1236, and George JT, PhD thesis (University of Edinburgh record).
- Chen F et al., Curr Diab Rep 2025;25:4, doi:10.1007/s11892-024-01557-z.
- Mortazavi SM et al., Topically applied GHK as an anti-wrinkle peptide, BioImpacts 2024, doi:10.34172/bi.30071.
- World Anti-Doping Agency, 2026 Prohibited List.
- Barbell Medicine summary of the STEP 1 body-composition data, GLP-1s and muscle loss.
Frequently Asked
Very little. A 2025 systematic review found 36 studies on BPC-157 in orthopaedic sports medicine, 35 of them preclinical. The only clinical study was an uncontrolled retrospective report of 12 patients with knee pain, and the authors said the data were not enough to propose evidence-based use guidelines.
No. Secretagogues and GHRH analogues prompt your own pituitary to release growth hormone, so the response depends on your physiology and feedback. We could not find randomized trials showing that research secretagogues build muscle or strength in healthy trained men.
We found no controlled human trials of TB-500 for muscle or tendon injury. It is marketed as a derivative of thymosin beta-4, but evidence for a parent molecule does not automatically apply to a fragment.
No. A COA reports what a lab found in a tested sample, typically identity and purity. It does not prove sterility unless that was tested, does not guarantee your vial matches the tested lot, and says nothing about human safety or effectiveness.
The strongest evidence belongs to FDA-approved drugs in their approved uses, such as tesamorelin for abdominal fat in HIV-associated lipodystrophy and GLP-1 medications for weight management. Most research-only peptides rest mainly on animal and cell studies.